TIL Therapy for Patients With Advanced Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

May 31, 2026

Conditions

Advanced Breast CancerAdvanced Lung Cancer

Interventions

BIOLOGICAL

Tumor-infiltrating lymphocytes

After NMA Lymphodepletion, autologous TILs will be intravenous infused into patients.

DRUG

IL-2

IL-2 will be subcutaneous administrated for 14 days following TILs infusion.